Clinical Trial Update: A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) [Phase 4]

View source ↗

Summary

This ClinicalTrials.gov entry reports a Phase 4, multicenter, open-label evaluation of the clinical effectiveness of the once-daily rivastigmine transdermal pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2011-07-26